Study of the efficacy and safety of ramelteon in insomnia of diabetes merger under the medical treatment of cancer patients

Study of the efficacy and safety of ramelteon in insomnia of diabetes merger under the medical treatment of cancer patients - Study of the efficacy and safety of ramelteon in insomnia of diabetes merger under the medical treatment of cancer patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014162

Enrollment

100

Registered

2014-06-04

Start date

2014-02-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia cancer patients under the medical treatment to be complicated by diabetes

Interventions

The group of oral administration before bedtime at 8 mg of ramelteon once once a day . Duration of treatment is 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: insomnia patients

Exclusion criteria

Exclusion criteria: Patients with hypersensitivity to Rozerem. Patients with advanced liver dysfunction. Patient during administration of fluvoxamine maleate.

Design outcomes

Primary

Measure	Time frame
Sleep evaluation questionnaire	—

Countries

Japan

Contacts

Public ContactToru Kitazawa

Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Division of Diabetes, Endocrinology and Metabolism

cickkitazawa@gmail.com03-3823-2101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026